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Abstract
Background: The contribution of DNA methylation to the metastatic process in colorectal cancers (CRCs) is unclear.
Methods: We evaluated the methylation status of 13 genes (MINT1, MINT2, MINT31, MLH1, p16, p14, TIMP3, CDH1, CDH13,
THBS1, MGMT, HPP1 and ERa) by bisulfite-pyrosequencing in 79 CRCs comprising 36 CRCs without liver metastasis and 43
CRCs with liver metastasis, including 16 paired primary CRCs and liver metastasis. We also performed methylated CpG island
amplification microarrays (MCAM) in three paired primary and metastatic cancers.
Results: Methylation of p14, TIMP3 and HPP1 in primary CRCs progressively decreased from absence to presence of liver
metastasis (13.1% vs. 4.3%; 14.8% vs. 3.7%; 43.9% vs. 35.8%, respectively) (P,.05). When paired primary and metastatic
tumors were compared, only MGMT methylation was significantly higher in metastatic cancers (27.4% vs. 13.4%, P=.013),
and this difference was due to an increase in methylation density rather than frequency in the majority of cases. MCAM
showed an average 7.4% increase in DNA methylated genes in the metastatic samples. The numbers of differentially
hypermethylated genes in the liver metastases increased with increasing time between resection of the primary and
resection of the liver metastasis. Bisulfite-pyrosequencing validation in 12 paired samples showed that most of these
increases were not conserved, and could be explained by differences in methylation density rather than frequency.
Conclusions: Most DNA methylation differences between primary CRCs and matched liver metastasis are due to random
variation and an increase in DNA methylation density rather than de-novo inactivation and silencing. Thus, DNA methylation
changes occur for the most part before progression to liver metastasis.
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Introduction
Colorectal cancers (CRCs) are the second leading cause of death
from cancer and the third most commonly diagnosed cancers in
the United States [1]. About 5% of the US population will develop
CRCs within their lifetime [2]. CRCs are frequently curable by
surgical resection when diagnosed at an early stage, while it is
difficult to cure when patients are first seen at an advanced stage.
Patients with metastatic CRCs have poor outcome with shortened
survival.
Most CRCs develop in a multistep manner through the
adenoma-carcinoma sequence over many years to decades [3].
The process often begins with inactivation of the APC/b-catenin
signaling pathway. Accumulation of specific genetic and epigenetic
events results in disease progression along three distinct clinico-
pathologic pathways involving DNA methylation, microsatellite
instability, and epigenetic-genetic interactions affecting mutations
of KRAS or BRAF oncogenes and the p53 tumor suppressor genes
[4,5].
The molecular mechanisms responsible for progression to CRC
metastasis are largely unknown. An early model postulated that
metastasis results from rare molecular events that provide the
ability to invade, disseminate and survive at distant sites [6] as a
result of clonal selection. This model predicts that some genetic or
epigenetic changes will uniquely characterize metastatic lesions as
compared with their primary. Recently, gene expression studies
suggested an alternative model in which the ability to metastasize
is an early event that can already be distinguished even in primary
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have been implicated in this process, but the molecular
mechanisms underlying these alterations are unknown. Recent
reports have also shown that DNA methylation has prognostic
implications in CRCs [8,9,10,11,12,13]. Patients with CRCs that
are microsatellite stable and have CpG islands methylator
phenotype (CIMP) tend to have a worse prognosis when compared
with other molecular subtypes of CRCs. Here, we test the
hypothesis that aberrant DNA methylation contributes to the
metastatic process in CRCs.
Materials and Methods
Tissue specimens and cell lines
We examined 79 sporadic CRCs comprising 36 CRCs without
liver metastasis (stage I–III) and 43 CRCs with liver metastasis
(stage IV/liver recurrence). A metachronous liver metastasis was
defined as a liver metastasis resected at least 12 months after
resection of their primary CRCs, otherwise we considered a
synchronous metastasis. Among the 43 patients, 16 had both
primary CRC and matched liver metastasis available for
evaluation. All tissue specimens were obtained from patients
who had undergone surgery or endoscopic biopsy at the M.D.
Anderson Cancer Center (n=64) or at the Showa University
Hospital (n=15). We excluded patients who had syndromic
familial predisposition (familial adenomatous polyposis or hered-
itary nonpolyposis colorectal cancer syndrome). Written informed
consent was obtained from all study patients. Tissue collection and
analyses were approved by the Institutional Review Board of the
University of Texas M.D. Anderson Cancer Center and the
Showa University School of Medicine.
Tissue samples and DNA preparation
We used 95 frozen samples (79 primary and 16 liver metastatic
tumors) from 79 patients with CRC. Frozen tissue samples were
harvested postoperatively or endoscopically and stored at 280uC.
Hematoxylin and eosin (H&E) stained slides from frozen tissue
blocks were reviewed by senior pathologists to evaluate the
distribution of tumor cells. Representative tumor samples
contained a minimum of 80% tumor cells. When colonic biopsy
specimens were obtained from patients, we used chromoendo-
scopy with pit pattern classification to accurately distinguish
between neoplastic and non-neoplastic area in the lesion [14].
DNA was extracted from the tissue samples using standard
proteinase K-phenol-chloroform methods.
A total of nine colon cancer cell lines (SW48, RKO, SW480,
HCT116, LoVo, Caco2, DLD1, and SW620) were obtained
from the American Type Culture Collection (ATCC, Manassas,
VA). All cells were cultured in recommended medium with 10%
fetal bovine serum in a humidified atmosphere containing 5%
CO2 at 37uC. Genomic DNA was extracted from these cell
lines and tissue samples using a standard phenol-chloroform
method.
Bisulfite-pyrosequencing for DNA methylation analysis
Bisulfite treatment was performed as previously described
[15]. Two or 3 ml of bisulfite treated DNA were used as template
for bisulfite polymerase chain reaction (PCR). We used a
quantitative pyrosequencing method for all DNA methylation
analysis as described previously [16,17]. Pyrosequencing mea-
sures the methylation status of several CpG sites in a given
promoter. We averaged the methylation percentage of all CpG
measured, because different CpG sites show highly concordant
methylation.
We evaluated the methylation status of 13 genes (MINT1,
MINT2, MINT31, MLH1, p16, p14 [18], TIMP3 [19], CDH1
[20], CDH13 [20,21], THBS1 [22], MGMT [23], HPP1 and
ERa [24]), which have been reported to be altered in primary or
metastatic CRCs [25]. All assays were designed to study regions
within 200 base pairs upstream or downstream of transcriptional
start sites. As mentioned below, eight genes were selected for
validation analysis of microarray results in 12 primary tumors and
matched liver metastases. Primer sequences and PCR conditions
for bisulfite pyrosequencing are summarized in the Table S1.
Methylation, mutation and definition of CIMP
For most analyses, we treated DNA methylation as a continuous
variable in this study. To define CIMP, however, we converted the
continuous values to categorical variables (positive/negative)
defined by a methylation density greater than 15%. CIMP was
defined using six genes (MINT1, MINT2, MINT31, p16, p14 and
MLH1) as described previously [17]. A tumor was considered
CIMP-positive if two or more of the CIMP markers demonstrated
methylation. All others were defined as CIMP-negative. All
mutational analysis (activating mutations in codon 12 of KRAS,
BRAF codon 600 and p53 exon 2 to exon 11) were previously
reported for this set of samples [4,26,27].
Table 1. Clinicopathological characteristics of patients with
primary colorectal carcinomas.
Liver metastasis
absence presence
(N=36) (N=43)
Gender Male 23 24
Female 12 19
Missing 1 0
Mean age (yrs) 66.3 62.2
(range) (40–81) (35–82)
Location Proximal 15 14
Distal 15 29
Missing 6 0
Stage* 1 4 0
(TNM) 2 22 3
38 8
40 3 2
Missing** 2 0
Liver metastasis synchronous NA 36
metachronous 7
Non-liver lymph node 8 30
metastasis lung 6
ovary NA 2
peritoneum 23
brain 1
*, Stage represents initial stage when primary tumors were surgically resected.
Eleven cases (three stage 2 and eight stage 3 CRCs) showed liver metastases
after surgery for primary tumors.
**, Two cases were known as colorectal cancers without distant metastasis. NA,
not applicable.
doi:10.1371/journal.pone.0027889.t001
DNA Methylation in Metastatic Colon Cancers
PLoS ONE | www.plosone.org 2 November 2011 | Volume 6 | Issue 11 | e27889Methylated CpG island amplification microarray (MCAM)
Methylated CpG island amplification (MCA) was performed for
three primary CRCs and their paired liver metastatic samples
randomly selected from the 16 paired primaries and liver
metastases. One was stage IV and two had liver recurrence. A
detailed protocol for MCA was described previously [28].
Microarray protocols, including labeling, hybridization and post-
hybridization washing procedures were as recommended by the
manufacturer and are available at http://www.agilent.com
(Figure S1). Amplicons from the liver metastases were labeled
with the Cy5 dye and cohybridized against amplicons from their
paired primary cancers labeled with the Cy3 dye on 4644 K
promoter microarrays purchased from Agilent Technologies
(Agilent, Santa Clara, CA) as described previously [29]. After
hybridization preparation for array slides, arrays were scanned on
an Agilent scanner and analyzed using Agilent Feature Extraction
software at the M. D. Anderson Microarray Core Facility.
Data analysis and statistics
Pyrosequencing provides a methylation level (%), which was
analyzed as a continuous variable for comparison of each gene
with clinicopathologic variables, and we computed mean, ranges,
and 95% confidence interval (95% CI). Z-score analysis was used
to normalize the methylation data of multiple genes and allow the
derivation of a mean methylation score. The Z-score of
methylation for each gene was calculated using the following
Figure 1. DNA methylation status of thirteen cancer-specific or age-related genes/CpG islands in primary CRCs without and with
liver metastasis. Each dot represents the methylation level of an individual sample. Horizontal lines represent mean methylation levels for each
group. *, P=.0005; **, P=.0113; #, P=.0452. LM-, primary CRCs without liver metastasis; LM+, primary CRCs with liver metastasis. CRCs, colorectal
cancers.
doi:10.1371/journal.pone.0027889.g001
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PLoS ONE | www.plosone.org 3 November 2011 | Volume 6 | Issue 11 | e27889Figure 2. A) DNA methylation status of thirteen cancer-specific or age-related genes/CpG islands in 16 primary CRCs and matched liver metastasis.
Each dot represents the methylation level of an individual sample. Horizontal lines represent mean methylation levels for each group. ", P=.013.
Primary, primary CRCs; Mets, liver metastasis. B) DNA methylation and mutation status in 16 primary CRCs and paired liver metastases. Each column
DNA Methylation in Metastatic Colon Cancers
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methylation density)/SD of methylation density. When analyzing
multiple genes, we used the average of the Z-score for each gene.
Differences in promoter methylation between two groups and
associations between methylation and clinicopathologic charac-
teristics were analyzed by the Mann-Whitney U test. The
incidence of CIMP or gene mutation and patient characteristics
were compared between tumor groups using the x2 test or Fisher’s
exact test when testing small numbers of samples. All tests were
two sided, and P,.05 was considered statistically significant.
Lowess normalization and data analysis of microarray data were
performed as described previously [29]. We defined hypermethy-
lation as normalized log2 ratio .1.0 (equivalent to ,2.0-fold liver
metastasis/primary tumor signal intensity) based on previous
validation experiments.
Results
DNA methylation and mutation status in primary CRCs
with or without liver metastasis
Table 1 shows the clinicopathologic characteristics of the 79
studied CRC patients with and without liver metastasis. Of 43
CRCs with liver metastasis, 36 had synchronous liver metastasis,
whereas 7 were metachronous. The 7 liver metastasis specimens
were obtained 12 to 46 months after resection of primary. There
were no significant differences in gender, age and tumor location
between CRC patients with and without liver metastasis. Figure 1
shows the methylation status of the 13 genes investigated by
bisulfite/pyrosequencing in relation to stage of primary CRC and
to liver metastasis. Methylation of p14, TIMP3 and HPP1 in
primary tumors progressively decreased from absence to presence
of liver metastasis (13.1% [95% CI, 19.1% to 7.1%] vs. 4.3%
[95% CI, 6.8% to 1.7%]; P,.001; 14.8% [95% CI, 21.3% to
8.2%] vs. 3.7% [95% CI, 5.3% to 2.1%]; P=.011; 43.9% [95%
CI, 49.4% to 38.3] vs. 35.8% [95% CI, 41.6% to 30.0%];
P=.045, respectively). The other genes showed no significant
differences by liver metastasis.
We next classified tumors as CIMP-positive or CIMP-negative
based on methylation of 2 or more CIMP-related genes (MINT1,
2, 31, p16, p14 and MLH1) and we observed no significant
difference in the frequency of CIMP between primary CRCs
without and with liver metastasis (15/36, 42% vs. 13/43, 30%).
When we used Z-score analysis to normalize the data of CIMP-
related genes, there was no significant difference in the average of
Z-scores for CIMP-related genes between CRCs without and with
liver metastasis (1.5 [95%CI, 2.5 to 20.7] and 1.5 [95%CI, 2.2 to
0.7], P=.545). We also found no significant differences in the
frequency of BRAF and KRAS mutations between primary CRCs
without and with liver metastasis (3/36, 8% vs. 2/43, 5% for
BRAF mutations; 19/36, 53%; 21/43, 49% for KRAS mutations).
BRAF and KRAS mutations were mutually exclusive.
We also evaluated DNA methylation and mutation status of
primary CRCs with synchronous and metachronous liver
metastasis. Only MINT1 methylation was significantly higher in
primary tumors with synchronous than those with metachronous
liver metastasis (15.8% [95% CI, 22.6% to 8.9%] vs. 4.3% [95%
CI, 12.9% to 20.9%]; P=.0121). However, we observed no
significant differences in DNA methylation or mutation of the
other genes between primary CRCs with synchronous and those
with metachronous liver metastasis.
DNA methylation and mutation status in matched 16
paired primary CRCs and liver metastases
We measured DNA methylation for 13 genes in 16 paired
primary and liver metastasis specimens which resulted in 205
measurement pairs (Data for THBS1 methylation in one primary
and two metastatic tumors was not available). The data are
shown in Figure 2. When analyzed as a continuous variable
(Fig. 2A), only MGMT methylation was significantly higher in
liver metastases than their matched primary CRCs (27.4% [95%
CI, 42.6% to 12.2%] vs. 13.4% [95% CI, 22.8% to 4.2%],
P=.013). Fig. 2B shows the data with methylation analyzed as a
categorical variable. Concordant and discordant methylation
between primary and metastatic tumors were respectively
observed in 47 (23%) and 22 (11%) of 205 measurement pairs
using a 15% cut-off value for methylation densities (Fig. 2B). A
total of 183 (89%) measurement pairs showed concordant
methylation status (methylation or lack of methylation). Discor-
dant mutation was found in 2/11 (18%) tumor pairs with KRAS
mutation and these two cases showed KRAS mutation in the
primary tumors only (Fig. 2B). However, no discordant mutation
status of p53 was observed.
represents a separate gene locus indicated on top. Each row represents a primary or metastatic tumor. Average methylation density of less than 15%
are shown in green, 15 to 50% in yellow and over 50% in red. Black square, presence of mutation; white square, absence of mutation; ND, not
detected; NA, not applicable. C) Differences in methylation between primary CRCs and matched liver metastases. Red boxes denote an increase in
methylation levels at metastatic tumors of more than two times higher when compared with primary tumors and the methylation level of at least one
of the tumors is greater than 15%; green boxes show decrease of methylation levels at metastatic tumors of more than two times lower than primary
tumors and the methylation level of at least one of the tumors is greater than 15%. White boxes are all others.
doi:10.1371/journal.pone.0027889.g002
Table 2. Patient’s characteristics analyzed by MCAM.
Patient Gender Age Tumor Size Histology Liver Duration*
Genes methylated
at
(yrs) location (mm) metastasis (months) liver metastasis
A F 65 Proximal 40 Mod synchronous 3 307 (4.7%)**
B M 73 Proximal 51 Mod-Muc metachronous 46 716 (10.9%)**
C M 60 Distal 23 Mod metachronous 12 427 (6.5%)**
*, Duration between surgical resection for primary cancer and surgical resection for liver metastasis.
**, A vs. B; B vs. C; A vs. C;
p,.0001. Mod, moderately differentiated adenocarcinoma; Muc, mucinous carcinoma; NA, not applicable.
doi:10.1371/journal.pone.0027889.t002
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between primary and metastatic tumors (Fig. 2C). When tumor
pairs had a greater than two-fold difference in methylation level
and the methylation level of at least one of the tumors was greater
than 15%, we considered this a meaningful difference in
methylation. Increased and decreased methylation in liver
Figure 3. Microarray analysis of hypermethylated genes in liver metastatic cancers. A) The Venn diagram shows the overlap and
differences in methylated genes of liver metastasis in three patients. A total number of 6528 genes were analyzed by 18340 microarray probes
recognizing promoter CpG islands. B) Dendrogram and heat map overview of unsupervised hierarchical cluster analysis of DNA methylation in liver
metastatic cancers of three patients. Each cell represents DNA methylation status of a gene in an individual sample. Red and green in cells reflect high
and low methylation level, respectively, as shown in the scale bar (log2-transformed scale) below the matrix.
doi:10.1371/journal.pone.0027889.g003
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measurement pairs, respectively. The only gene that had
consistent differences was MGMT, which had increased methyl-
ation in liver metastases in 5/16 cases. However, 4 of these 5 cases
showed methylation in the primary tumor as well, with an increase
in methylation density in the paired liver metastasis. Of the 5
cases, 3 had synchronous liver metastases and 2 were metachro-
nous.
Genome-wide DNA methylation analysis in primary CRCs
and matched liver metastasis
We used MCAM in three paired primary tumors and liver
metastasis (Table 2). This microarray determines the methylation
status of 6528 genes, of which 5940 (91%) have CpG islands
within 1 kb from the transcription start sites. Figure S1 shows a
representative example demonstrating gains of methylation in the
metastasis sample in one case. Overall, MCAM analysis showed
that 307 (4.7%), 716 (10.8%), and 427 (6.5%) genes were
differentially hypermethylated in each liver metastasis sample,
with 90 (1.3%) genes being commonly differentially hypermethy-
lated in each liver metastasis (Fig. 3). Of the three tumor pairs, one
was synchronous and two were metachronous metastatic tumors.
Interestingly, the numbers of differentially hypermethylated genes
in the liver metastatic tumors increased with increasing time
between resection of the primary and resection of the liver
metastasis (Table 2). These differences were statistically significant
(P,0.0001) (Table 2).
To validate the results and determine whether these changes
were a result of selection or random drift with time, we selected
eight hypermethylated genes that had an average log2 ratio value
.1.9 in all 3 tumors and analyzed them by bisulfite-pyrosequenc-
ing in 12 paired primary and liver metastases of CRCs. As shown
in Figure 4, all 8 genes were very commonly methylated in colon
cancer cell lines and in primary tumors. In the three pairs analyzed
by MCAM, 12/24 measurements showed increased methylation
by pyrosequencing by our strict criteria described above, and most
of the other 12 measurements also showed increased methylation
(albeit to lower levels), thus validating the MCAM results.
However, when studying all cases, we observed no significant
differences in the methylation level of the eight genes between
primary and liver metastatic cancers (Z-score: 0.116 [95% CI,
0.536 to 20.304 and 20.116 [95% CI, 0.362 to 20.595],
respectively; P=.583) (Fig. 4). Also, these differences were not
associated with time interval from resection of the primary tumor
to resection of the liver metastasis. Overall, of 96 measurements, 4
measurements (4%) showed an increase, 16 measurements (17%)
showed a decrease, and 76 measurements (79%) showed no
change. Thus, most of the methylation differences between
primary CRCs and matched liver metastasis reflect random
variation rather than selection for particular genes in the
metastasis process.
Discussion
Promoter DNA methylation and associated silencing is a frequent
and early event in colorectal carcinogenesis [30]. Some of the genes
affected, such as MLH1, p16 and p14, clearly contribute physiolog-
ically to the neoplastic phenotype [31,32,33]. The occurrence of liver
metastasis leads to a poor clinical outcome in CRCs, and here we
sought to determine the possible involvement of DNA methylation in
the process. Generally, we found that methylation does not increase
withincreasingstage, confirmingthatitisanearly event. Importantly,
wedid find substantialdriftinmethylation patternsinlivermetastases
compared to primary tumors, but the patterns at loci examined
appeared more consistent with random flux rather than selection for
specific genes.
When we looked at the differences in methylation between
primary tumors with and without liver metastases, methylation
levels of p14, TIMP3 and HPP1 progressively decreased from
early-stage to late-stage disease. We have previously found that
methylation of p14 and TIMP3 is the markers for predicting
CIMP1 [4]. Thus, this consistent decrease of methylation in CRCs
with liver metastasis likely represents the generally good prognosis
of CIMP1 cancers which rarely progress to advanced disease [11].
Depletion of TIMPs has been reported to abrogate normal
apoptotic programs, enhance primary tumor growth and angio-
genesis, invasiveness, and metastasis and possibly contribute to all
Figure 4. DNA methylation analysis for eight genes identified
by MCAM in 12 paired primary CRCs and liver metastasis. Each
column represents a separate gene locus indicated on top. Each row
represents a primary or metastatic tumor, normal tissue type or colon
cancer cell. Average methylation densities of less than 15% are shown
in white, 15 to 50% in gray and over 50% in black. PBL, peripheral
blood.
doi:10.1371/journal.pone.0027889.g004
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data are not consistent with a major role for TIMP3 in CRC
metastasis. It is possible that other members of the TIMP family
such as TIMP1 and TIMP2 might be more important for the liver
metastatic process in CRCs [35].
Overall, we quantitatively compared the methylation status of
21 genes (13 candidates and 8 from the microarrays) between
paired primary and liver metastasis lesions. Of these, only MGMT
methylation was consistently higher in the liver metastases than
primary tumors. Of 16 pairs studied, five (31%) showed
significantly higher MGMT methylation at the metastatic site.
Of these five tumor pairs, four pairs demonstrated MGMT
methylation at both sites (primary and liver metastatic tumors)
with an increase in methylation density. Increased density of
methylation could be explained by multiple different factors –
increased proportion of methylated cells, switch from monoallelic
to biallelic methylation or even differences in the degree of normal
cell contamination of the tumor samples. Our data do not allow us
to distinguish these possibilities and a larger series with more
detailed analysis is needed to confirm our results and address the
issue.
MGMT protein stoichiometrically repairs O
6-alkylG-DNA
adducts [36]. Inactivation of MGMT by promoter-methylation
can lead to G to A transition mutations in several genes, including
KRAS [37]. Thus, MGMT methylation could be associated with
the metastatic process by increasing the rate of mutations.
However, this has not yet been convincingly demonstrated in
CRCs. Park et al. have reported that MGMT methylation in
patients with gastric carcinoma is significantly associated with
lymph-node metastasis, tumor stage and disease free survival [38].
However, another study showed significant association between
MGMT methylation and improved overall survival in diffuse large
B-cell lymphoma [39]. Thus, the relationship between MGMT
methylation and metastasis or tumor prognosis might be tissue
specific, or possibly coincidental.
Our genome-wide analysis of hypermethylated genes at the liver
metastatic tumor revealed that 7.4% (range, 4.7% to 10.9%) of the
genes showed hypermethylation in the metastatic tumors and
1.3% was commonly hypermethylated among three patients.
These numbers are quite large at face value, but when we
validated the data by bisulfite-pyrosequencing, a change in
methylation density was the explanation in most cases. One
additional clue to explain this finding came from an analysis of
resection time differences between the primary and metastatic
lesions. Thus, the percentage of hypermethylated genes at liver
metastasis was significantly higher in metachronous metastasis
than in synchronous metastasis. In one patient, the time between
surgery for the primary tumor and the liver metastasis was 46
months and 10.9% of genes analyzed using MCAM showed
differential hypermethylation at the liver metastatic tumor.
MCAM data in a patient with synchronous metastasis revealed
4.7% differential hypermethylated genes. Given that population
doubling (reflected by patient age) is a prime determinant of
methylation in normal and neoplastic colon, [40] our data could
be explained by continued accumulation of methylation at the
metastatic site. Overall, looking at methylation frequency, we find
few differences between primary tumors and liver metastases,
suggesting that aberrant DNA methylation is a very early event
and that tumor cells acquire methylation changes before
progression to liver metastasis. We cannot exclude the possibility
that a few rare genes are highly selected for during the process of
metastasis, but discovering these will require whole-genome
methylation analysis technology that is more quantitative than
what is currently available.
In summary, our results indicate that methylation frequency
between primary tumors and matched liver metastasis is similar,
suggesting that tumor cells acquire methylation changes before
progression to liver metastasis. While we cannot rule out rare
consistent changes, it appears that DNA methylation frequency is
very stable over time in CRC.
Supporting Information
Figure S1 Scatter plot analysis of signal intensity (log
scale) between DNA samples of liver metastasis (y-axis)
and primary tumors (x-axis) from MCAM.
(TIF)
Table S1 Summary of the PCR and sequencing primers.
Primer sequences and PCR condition for MINT31, p16 and p14
were previously described.
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